Compare Hut 8 Corp (HUT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Twist Bioscience Corp — how do they compare? Hut 8 Corp trades at $108.8 (market cap $11.36B), while Twist Bioscience Corp trades at $94.11 (market cap $5.45B). The key difference: Hut 8 Corp is far larger — about 2.1× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals.
| HUT | TWST | |
|---|---|---|
Market Cap | $11.36B | $5.45B |
Sector | Technology | Health |
52-Week High | $133.02 | $102.88 |
52-Week Low | $19.45 | $24.16 |
Enterprise Value | $11.63B | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $100.93, up 10.37% in the past 24 hours, with a bearish technical signal from moving averages and oscillators. The company reported a net loss of $226.15 million in 2025 despite revenue of $235.12 million, though it beat EPS estimates in two of the last three quarters. Recent news highlights its pivot to AI infrastructure, including a $4.25 billion bond issuance for data center projects (PRNewsWire, 2026-06-09).
Analyst consensus is strongly bullish with a $138.89 price target, but high valuation ratios and persistent losses pose risks. The stock's outlook hinges on successful execution of its digital infrastructure strategy, though cash flow challenges and competitive pressures remain key concerns for investors.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
